Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics entities : Karyopharm therapeutics inc. save search
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 20:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: -1.9%
H: 0.65%
C: -10.0%
nasdaq grants therapeutics
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.26%
H: 18.38%
C: 12.5%
biopharma global
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Published: 2024-02-29 (Crawled : 12:30) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.0%
H: 2.26%
C: -12.78%
company year financial results
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
Published: 2024-02-22 (Crawled : 15:30) - biospace.com/
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.83%
H: 2.05%
C: -7.38%
report year financial results
PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 - Exclusive Report by InsightAce Analytic
Published: 2024-02-21 (Crawled : 09:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.88%
H: 1.75%
C: -0.29%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: -1.65%
H: 3.36%
C: 1.68%
CKPT | $1.595 -4.49% -4.7% 470K
|
Health Technology
|
| O: 0.0%
H: 1.26%
C: -3.03%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.01%
H: 1.1%
C: 1.1%
report year reach market
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 1.08%
H: 18.52%
C: 14.29%
nasdaq grants therapeutics
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.14%
H: 10.9%
C: 9.56%
revenue
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 12:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
conference
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.98%
H: 1.1%
C: -8.45%
nasdaq grants therapeutics
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
Published: 2023-12-14 (Crawled : 02:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 3.07%
H: 9.75%
C: 5.02%
xpovio drug
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
Published: 2023-12-11 (Crawled : 02:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: -1.36%
H: 12.13%
C: -8.31%
durability study
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Published: 2023-12-06 (Crawled : 09:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.81%
H: 8.51%
C: 3.74%
xpovio approval treatment
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-01 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants therapeutics
Global Glioma Treatment Market Research Report 2023: Breakthrough Oncolytic Virus Therapy Offers New Hope for Glioma Patients - Forecast to 2027 and 2032
Published: 2023-11-27 (Crawled : 23:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 4.0%
H: 1.93%
C: -7.72%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.03%
H: 0.85%
C: 0.44%
report hope treatment research global virus therapy market
Karyopharm to Participate at Upcoming Investor Conferences
Published: 2023-11-08 (Crawled : 21:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 3.05%
H: 0.17%
C: -10.3%
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Published: 2023-11-06 (Crawled : 12:00) - prnewswire.com
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 3.4%
H: 5.47%
C: -4.36%
tp53 cancer study
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 1.78%
H: 6.8%
C: -4.86%
meeting
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.39%
H: 0.32%
C: -0.93%
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.92%
H: 6.08%
C: -3.35%
collaboration trial
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 2.71%
H: 3.0%
C: -3.47%
report financial results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.